Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.
Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Meditz AL, et al. Among authors: cooper da. J Infect Dis. 2011 Feb 15;203(4):442-51. doi: 10.1093/infdis/jiq085. Epub 2011 Jan 18. J Infect Dis. 2011. PMID: 21245157 Free PMC article.
Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2.
Zaunders JJ, Moutouh-de Parseval L, Kitada S, Reed JC, Rought S, Genini D, Leoni L, Kelleher A, Cooper DA, Smith DE, Grey P, Estaquier J, Little S, Richman DD, Corbeil J. Zaunders JJ, et al. Among authors: cooper da. J Infect Dis. 2003 Jun 1;187(11):1735-47. doi: 10.1086/375030. Epub 2003 May 15. J Infect Dis. 2003. PMID: 12751031
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Among authors: cooper da. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams. Eron JJ, et al. Among authors: cooper da. Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7. Lancet Infect Dis. 2013. PMID: 23664333 Free PMC article. Clinical Trial.
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age.
Vanhems P, Routy JP, Hirschel B, Baratin D, Vora S, Maenza J, Carr A, Trépo C, Touraine JL, Gillibert RP, Collier AC, Cooper DA, Vizzard J, Sékaly RP, Fabry J, Perrin L; Collaborative Group. Vanhems P, et al. Among authors: cooper da. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):318-21. doi: 10.1097/00126334-200211010-00007. J Acquir Immune Defic Syndr. 2002. PMID: 12439207
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Bloch MT, Smith DE, Quan D, Kaldor JM, Zaunders JJ, Petoumenos K, Irvine K, Law M, Grey P, Finlayson RJ, McFarlane R, Kelleher AD, Carr A, Cooper DA. Bloch MT, et al. Among authors: cooper da. J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202. doi: 10.1097/01.qai.0000219779.50668.e6. J Acquir Immune Defic Syndr. 2006. PMID: 16688094 Clinical Trial.
823 results